PHS
JUNO

PFM Health Sciences’s Juno Therapeutics, Inc. JUNO Stock Holding History

PFM Health Sciences’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,850,820
Closed -$84.6M – 109
2017
Q4 		$84.6M Buy
1,850,820
+400,213
+28% +$20M 2.01% 13
2017
Q3 		$65.1M Buy
1,450,607
+1,335,912
+1,165% +$45.5M 1.28% 28
2017
Q2 		$3.43M Hold
114,695
– – 0.09% 86
2017
Q1 		$2.54M Sell
114,695
-4,973
-4% -$107K 0.06% 95
2016
Q4 		$2.26M Sell
119,668
-1,004,617
-89% -$24.6M 0.06% 91
2016
Q3 		$33.7M Buy
+1,124,285
New +$35M 0.99% 42
2016
Q1 		– Sell
-150,684
Closed -$6.63M – 100
2015
Q4 		$6.63M Buy
150,684
+77,053
+105% +$3.82M 0.2% 60
2015
Q3 		$3M Sell
73,631
-45,323
-38% -$1.99M 0.08% 61
2015
Q2 		$6.34M Sell
118,954
-395,631
-77% -$21M 0.16% 72
2015
Q1 		$30.5M Sell
514,585
-116,457
-18% -$5.65M 0.84% 45
2014
Q4 		$33M Buy
+631,042
New +$28.2M 0.77% 46

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

PFM Health Sciences's JUNO Position: Q1 2018 in Review

PFM Health Sciences sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,850,820 shares — an estimated $84.6M sold.

PFM Health Sciences first reported a position in JUNO in Q4 2014 and held it in 11 quarters. The position peaked at $84.6M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • PFM Health Sciences reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • PFM Health Sciences sold 1,850,820 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $84.6M.
  • PFM Health Sciences first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 11 quarters.
  • PFM Health Sciences's Juno Therapeutics, Inc. position peaked at $84.6M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on PFM Health Sciences's 13F filing for Q1 2018, filed 15 May 2018.